Title:
CD33 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CD33 POSITIVE MALIGNANCIES
Document Type and Number:
WIPO Patent Application WO/2020/243713
Kind Code:
A3
Abstract:
Chimeric antigen receptors targeted to CD33 are described together with their use in treating various cancers and in reducing myeloid derived suppressor cells in a patient.
Inventors:
XUE TONGYUAN (US)
HORNE DAVID A (US)
BUDDE LIHUA ELIZABETH (US)
FORMAN STEVE (US)
DEL REAL MARISSA M (US)
HORNE DAVID A (US)
BUDDE LIHUA ELIZABETH (US)
FORMAN STEVE (US)
DEL REAL MARISSA M (US)
Application Number:
PCT/US2020/035579
Publication Date:
January 07, 2021
Filing Date:
June 01, 2020
Export Citation:
Assignee:
HOPE CITY (US)
XUE TONGYUAN (US)
HORNE DAVID A (US)
BUDDE LIHUA ELIZABETH (US)
FORMAN STEVE (US)
DEL REAL MARISSA M (US)
XUE TONGYUAN (US)
HORNE DAVID A (US)
BUDDE LIHUA ELIZABETH (US)
FORMAN STEVE (US)
DEL REAL MARISSA M (US)
International Classes:
C07K14/725; C12N15/62
Domestic Patent References:
| WO2018213337A1 | 2018-11-22 | |||
| WO2017062604A1 | 2017-04-13 | |||
| WO2018075989A1 | 2018-04-26 |
Foreign References:
| CN105384823A | 2016-03-09 |
Other References:
DINA SCHNEIDER ET AL: "A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia", FRONTIERS IN ONCOLOGY, vol. 8, 22 November 2018 (2018-11-22), CH, XP055737977, ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00539
Attorney, Agent or Firm:
MEIKLEJOHN, Anita L. et al. (US)
Download PDF:
Previous Patent: PROCASPASE-3 ACTIVATION AND IMMUNOTHERAPY FOR TREATMENT OF CANCER
Next Patent: ADDITIVE MANUFACTURING COMPOSITIONS AND METHODS
Next Patent: ADDITIVE MANUFACTURING COMPOSITIONS AND METHODS